RESUMEN
Mesenchymal chondrosarcoma (MCS) is an infrequent malignancy of bone and soft tissue that is characterized by a peculiar bimorphic histologic pattern with areas of undifferentiated malignant small cells surrounding well-differentiated cartilaginous islands. Involvement of the large vessels is a rare occurrence. Here, we report a case of MCS arising from the femoral vein that was treated by wide-margin resection combined with autogenous vein revascularization and then followed up for 8 years. The long-term postoperative results showed distant metastasis to the pancreas and both lobes of the lung, without recurrence at the primary site. This case indicates that for MCS arising from the femoral vein, although wide-margin resection combined with autogenous vein revascularization may avoid recurrence at the primary site, this treatment strategy has no obvious benefit for controlling long-term distant metastases.
Asunto(s)
Condrosarcoma Mesenquimal/secundario , Vena Femoral/patología , Neoplasias Pulmonares/secundario , Neoplasias Pancreáticas/secundario , Neoplasias Vasculares/patología , Adulto , Biomarcadores de Tumor/análisis , Biopsia , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/cirugía , Vena Femoral/cirugía , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/química , Masculino , Pancreatectomía , Neoplasias Pancreáticas/química , Neoplasias Pancreáticas/cirugía , Vena Safena/trasplante , Factores de Tiempo , Tomografía Computarizada por Rayos X , Trasplante Autólogo , Resultado del Tratamiento , Neoplasias Vasculares/química , Neoplasias Vasculares/cirugíaRESUMEN
Primary mesenchymal chondrosarcoma of the kidney is rare, and it shows distinct undifferentiated tumor cells and well differentiated cartilagenous components. Also assident infiltrating urothelial carcinoma of the ureter is an extremely rare cancer. We report a case of primary mesenchymal chondrosarcoma occurring in the left kidney with an ipsilateral and distinct distal ureteric implant, and a coexisting infiltrating urothelial carcinoma of the ureter in a 64-year-old man. Histopathological examination and immunohistochemical studuies showed the classic features of mesenchymal chondrosarcoma in kidney, as well as a few infiltrating urothelial in ureter. Multitarget fluorescence in situ hybridization (FISH) suggested that the development of the urothelial carcinoma in the ureter may be triggered or induced by the chondrosarcoma component. The patient died 2 month after left nephro-ureterectomy. This is the first reported case of a primary mesenchymal chondrosarcoma of the kidney with coexisting infiltrating urothelial carcinoma of the ureter. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1522835667751019.
Asunto(s)
Carcinoma/patología , Condrosarcoma Mesenquimal/patología , Neoplasias Renales/patología , Neoplasias Primarias Múltiples/patología , Uréter/patología , Neoplasias Ureterales/patología , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Carcinoma/química , Carcinoma/genética , Carcinoma/cirugía , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/genética , Condrosarcoma Mesenquimal/cirugía , Resultado Fatal , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Neoplasias Renales/química , Neoplasias Renales/genética , Neoplasias Renales/cirugía , Masculino , Persona de Mediana Edad , Neoplasias Primarias Múltiples/química , Neoplasias Primarias Múltiples/genética , Neoplasias Primarias Múltiples/cirugía , Nefrectomía , Resultado del Tratamiento , Uréter/química , Uréter/cirugía , Neoplasias Ureterales/química , Neoplasias Ureterales/genética , Neoplasias Ureterales/cirugíaRESUMEN
Extraskeletal mesenchymal chondrosarcoma (EMC) is a rare and a malignant chondrogenic neoplasm. As a particularity of this neoplasm, about one-third of the cases develop outside the bone, with intramuscular site being a very rare location for development of EMC. The diagnosis of mesenchymal chondrosarcoma can be very challenging, especially in cases without conspicuous cartilaginous differentiation. In such cases its distinction from other small cell mesenchymal neoplasms cannot be safely established. This, however, is of major clinical interest as it implicates different treatment protocols as well as a different prognosis. We hereby present a case of EMC at a unusual location in a 23-year-old female with the purpose to highlight its morphologic features and to discuss its differential diagnosis.
Asunto(s)
Condrosarcoma Mesenquimal/patología , Neoplasias de los Músculos/patología , Adulto , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/cirugía , Diagnóstico Diferencial , Femenino , Humanos , Neoplasias de los Músculos/química , Neoplasias de los Músculos/cirugía , Proteínas S100/análisis , Muslo/patología , Vimentina/análisis , Adulto JovenRESUMEN
Mesenchymal chondrosarcoma is an uncommon lesion of the bone and extraskeletal tissue involving very rarely the orbit. Histopathological features of this lesion include: undifferentiated mesenchymal cells with islands of mature hyaline cartilage. We present a case of a 23-year-old man with primary orbital mesenchymal chondrosarcoma (OMC) with an uncommon management. This anecdotic report could be a contribution to the understanding of this unusual tumor.
Asunto(s)
Condrosarcoma Mesenquimal/patología , Neoplasias Orbitales/patología , Biomarcadores de Tumor/análisis , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/cirugía , Humanos , Imagen por Resonancia Magnética , Masculino , Neoplasias Orbitales/química , Neoplasias Orbitales/cirugía , Adulto JovenRESUMEN
In this paper we report the 1st case of a congenital intracranial mesenchymal chondrosarcoma in a 2-month-old infant, apparently present at birth. A magnetic resonance image showed a large left parietal solid mass, while microscopy revealed a mixture of undifferentiated small cells and mature hyaline cartilage islands, positive for vimentin, S-100, and CD99. A surgical excision was performed but the patient died after a few weeks as a result of a rapid relapse of the tumor. We also review the pediatric cases (in patients less than 20 years old) of extraskeletal (intracranial) mesenchymal chondrosarcomas of the literature, with a focus on the most recent cytogenetic and immunohistochemical studies.
Asunto(s)
Neoplasias Encefálicas/congénito , Condrosarcoma Mesenquimal/congénito , Antígeno 12E7 , Antígenos CD/análisis , Biomarcadores de Tumor/análisis , Neoplasias Encefálicas/química , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/cirugía , Moléculas de Adhesión Celular/análisis , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/patología , Condrosarcoma Mesenquimal/cirugía , Resultado Fatal , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Recurrencia Local de Neoplasia , Proteínas S100/análisis , Vimentina/análisisRESUMEN
Mesenchymal chondrosarcoma (MCS) is a rare malignant neoplasm of bone or soft tissue origin, locally aggressive, rare in the oral cavity, of which fewer than 100 cases have been reported in the English literature. This is the first case described of this type of tumor affecting the coronoid process. The report describes a unique case of MCS in a 64-year-old woman who presented with swelling and pain at the left preauricular area just anterior to the left tragus. An orthopantomograph showed a large mass in the temporomandibular joint involving the left coronoid process and extending to the left ramus of the mandible. Biopsy and histopathologic examination revealed a biphasic pattern, composed of an undifferentiated small round-cell component surrounding a myxoid of malignant cartilage; a focally pericytic vascular pattern resembling hemangiopericytoma was observed. Immunohistochemical studies were positive for CD99, S-100, and CD45 and negative for desmin, actin, chromogranin, epithelial membrane antigen (EMA), and cytokeratin. The tumor was treated by extensive hemimandibulectomy followed by reconstruction of the area. There was no evidence of disease at the 8-year follow-up. Previously reported cases are reviewed as well.
Asunto(s)
Condrosarcoma Mesenquimal/patología , Neoplasias Mandibulares/patología , Antígeno 12E7 , Antígenos CD/análisis , Biomarcadores de Tumor/análisis , Antígenos CD57/análisis , Moléculas de Adhesión Celular/análisis , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/cirugía , Femenino , Humanos , Inmunohistoquímica , Neoplasias Mandibulares/química , Neoplasias Mandibulares/cirugía , Persona de Mediana Edad , Procedimientos Quirúrgicos Orales , Procedimientos Quirúrgicos Ortognáticos , Glicoproteínas de Membrana Plaquetaria/análisis , Radiografía , Proteínas S100/análisis , Trastornos de la Articulación Temporomandibular/diagnóstico por imagen , Trastornos de la Articulación Temporomandibular/patología , Trastornos de la Articulación Temporomandibular/cirugía , Tetraspanina 30 , Vimentina/análisisRESUMEN
PURPOSE: To report the first case of congenital extraskeletal mesenchymal chondrosarcoma arising in the orbit. DESIGN: Interventional case report and review of the literature. METHODS: Ophthalmologic examination and computed tomography scan of the orbit were performed. Histologic and histochemical examination and immunohistochemistry of the biopsy specimen were evaluated. MAIN OUTCOME MEASURES: Ocular and systemic disease control. RESULTS: A 5-month-old girl was seen with a papillomatous lesion in the right lower tarsal conjunctiva present from birth. Histologic examination demonstrated an admixture of undifferentiated mesenchymal cells and islands of mature hyaline cartilage, and immunohistochemistry studies revealing positivity for vimentin and S-100 were consistent with the diagnosis of mesenchymal chondrosarcoma. The patient was treated with combined chemotherapy (ifosfamide, epirubicin, and cisplatin), radiotherapy, and surgery (exenteration). She is alive with no evidence of disease after 4 years of follow-up. Facial asymmetry and dental malformations have developed as late effects. Further reconstructive surgery is planned for the malformations. CONCLUSIONS: Extraskeletal mesenchymal chondrosarcoma in the orbit is extremely rare. This study reports the first case of congenital extraskeletal mesenchymal chondrosarcoma arising in the orbit (also the youngest patient) both in skeletal and extraskeletal sites. Multimodality treatment (surgery, chemotherapy, and radiotherapy) may lead to long-term survival.
Asunto(s)
Condrosarcoma Mesenquimal/congénito , Neoplasias Orbitales/congénito , Biomarcadores de Tumor/análisis , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/diagnóstico por imagen , Condrosarcoma Mesenquimal/terapia , Terapia Combinada , Femenino , Humanos , Recién Nacido , Neoplasias Orbitales/química , Neoplasias Orbitales/diagnóstico por imagen , Neoplasias Orbitales/terapia , Tomografía Computarizada por Rayos XRESUMEN
Over the last decade, a number of "master regulator" genes that control distinct pathways of mesenchymal differentiation have been discovered. These genes are expressed early during embryogenesis and initiate a cascade of gene expression responsible for specific cell lineage commitment. Thus, identification of their products may allow the classification of seemingly primitive, morphologically uncommitted tumors such as small blue round cell tumors. The transcription factor Sox9 has been demonstrated to be a master regulator of the differentiation of mesenchymal cells into chondrocytes. For this reason, we examined the utility of Sox9 in distinguishing mesenchymal chondrosarcoma (a small cell malignancy thought to be derived from primitive chondroprogenitor cells) from other primitive small cell malignancies. Representative sections from 90 cases of small blue round cell tumors (22 mesenchymal chodrosarcoma, 10 neuroblastomas, 11 rhabdomyosarcomas, 9 Ewing's sarcomas/primitive neuroectodermal tumors, 5 desmoplastic small round cell tumors, 7 small cell carcinomas, 6 Merkel cell carcinomas, 6 small cell osteosarcomas, 7 diffuse large B-cell lymphomas, 7 lymphoblastic leukemias/lymphomas, and 5 extraskeletal myxoid chondrosarcomas) were immunohistochemically stained with antibodies to Sox9 protein. All but 1 mesenchymal chondrosarcoma showed positive nuclear staining in both primitive mesenchymal and cartilaginous components of the tumor. All other types of small blue round cell tumors, as well as the lymphomas and leukemias, were negative for Sox9 protein. These findings confirm that mesenchymal chondrosarcoma has phenotypic features corresponding to the early condensational phase of cartilaginous differentiation. More important, Sox9 may serve as a useful tool in the differentiation of small cell malignancies.
Asunto(s)
Condrosarcoma Mesenquimal/diagnóstico , Proteínas del Grupo de Alta Movilidad/análisis , Factores de Transcripción/análisis , Adolescente , Adulto , Anciano , Secuencia de Aminoácidos , Carcinoma de Células de Merkel/química , Cartílago/patología , Diferenciación Celular , Núcleo Celular/química , Niño , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/clasificación , Diagnóstico Diferencial , Femenino , Proteínas del Grupo de Alta Movilidad/inmunología , Humanos , Inmunohistoquímica , Leucemia Linfoide , Masculino , Mesodermo/patología , Persona de Mediana Edad , Datos de Secuencia Molecular , Metástasis de la Neoplasia , Neuroblastoma/química , Osteosarcoma/química , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Fenotipo , Leucemia-Linfoma Linfoblástico de Células Precursoras/química , Rabdomiosarcoma/química , Factor de Transcripción SOX9 , Sarcoma de Ewing/química , Sensibilidad y Especificidad , Factores de Transcripción/inmunologíaRESUMEN
Primary tumours of the meninges with a relatively high tendency for malignant behaviour are uncommon in childhood. This study concerns 18 cases of meningeal tumours in children under the age of 16, of which 13 were meningiomas and five were other tumours arising in the meninges. Meningiomas showed a preponderance in females as in adult series, and the majority were supratentorial in localisation. The percentage of meningeal tumours and meningiomas among all brain tumours in our centre were 3.72% and 2.69%, respectively. Four out of 13 meningiomas were fibroblastic, four were transitional, one was meningothelial, two were psammomatous and two were papillary meningiomas. Seven (38.8%) out of 18 tumours showed anaplastic features, including two papillary meningiomas, two hemangiopericytomas, one mesenchymal chondrosarcoma, one pleomorphic sarcoma and one anaplastic meningeal tumour. Papillary meningiomas with hemangiopericytoma-like solid areas were seen frequently in our cases (15.3%). Meningoangiomatosis was associated with two meningeal tumours. MIB1 (Ki-67) labelling indices (LIs) ranged between 0% and 13.6% (mean 1.83%) in benign, and between 1% and 20% (mean 7.2%) in malignant tumour, including papillary meningiomas. Mean MIB-1 LIs were 5.61% and 1.14% in non-recurrent and recurrent cases, respectively. MIB-1 LIs showed significant differences between benign and malignant meningeal tumours but no significant correlation either with prognosis or recurrence. Despite the fact that brain tumours are among the most common neoplasms of childhood, meningeal tumours are rare lesions, accounting for less than 2% of published series of intracranial neoplasms in childhood [5, 8, 18, 24, 30, 32]. It has been suggested that the clinical and pathological characteristics of meningiomas in this age group differ from those of adults [14, 18, 24, 45]. Besides meningiomas, there are a few reports of other meningeal tumours in childhood and difficulties in differential diagnosis may arise within this group, especially in anaplastic tumours [11, 13, 32, 44, 46]. One of the major problems in meningiomas and some tumours arising in the meninges is the discordance that arises between the histologic appearance of the tumour and behaviour [4]. Several studies have attempted to determine the proliferation potential of meningiomas, including immunohistochemical labelling with monoclonal antibodies to Ki-67, proliferating cell nuclear antigen (PCNA), and bromodeoxyuridine (BUdR); flow cytometric DNA analysis; or argyrophilic nucleolar organizer regions (AgNORs) counting [9, 10, 15, 19, 22, 26, 31, 35, 53]. The studies concerning proliferation markers have contradictory results [9, 10, 15, 26, 31, 42, 53]. MIB-1 detects the same or a similar epitope as the original antibody Ki-67 and reacts with a proliferation associated antigen expressed in all active parts of the cell cycle, G1, S, G2 and M (mitosis), but not in the G0 or quiescent phases [7]. In this study we examined the clinicopathological characteristics and MIB1 values of 18 meningeal tumours in children under the age of 16 years within the last 25 years (from 1970 to 1995).
Asunto(s)
Neoplasias Meníngeas/patología , Meningioma/patología , Proteínas Nucleares/análisis , Adolescente , Antígenos Nucleares , Biomarcadores de Tumor/análisis , Niño , Preescolar , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/patología , Condrosarcoma Mesenquimal/cirugía , Femenino , Hemangiopericitoma/química , Hemangiopericitoma/patología , Hemangiopericitoma/cirugía , Humanos , Técnicas para Inmunoenzimas , Antígeno Ki-67 , Masculino , Neoplasias Meníngeas/química , Neoplasias Meníngeas/cirugía , Meningioma/química , Meningioma/cirugía , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugíaRESUMEN
We report the first case of metastatic involvement of the skin by a soft tissue mesenchymal chondrosarcoma (MS). A 64-year-old man presented 15 months after resection of a 7.0 cm MS from his left forearm with a rapidly growing, erythematous nodule on the left side of the upper lip. The lesion was clinically interpreted as a keratoacanthoma. The histologic appearance was identical to that of the soft tissue MS; an immunohistochemical stain for CD99 was positive. Lung and bone metastases were subsequently documented. Our case expands the differential diagnosis of malignancies with cartilaginous differentiation that can involve the skin.
Asunto(s)
Condrosarcoma Mesenquimal/secundario , Queratoacantoma/diagnóstico , Neoplasias Cutáneas/secundario , Neoplasias de los Tejidos Blandos/patología , Antígeno 12E7 , Antígenos CD/análisis , Moléculas de Adhesión Celular/análisis , Condrosarcoma Mesenquimal/química , Condrosarcoma Mesenquimal/terapia , Terapia Combinada , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Cutáneas/química , Neoplasias de los Tejidos Blandos/química , Neoplasias de los Tejidos Blandos/terapiaRESUMEN
We report the case of a 93-year-old female who had developed a primary extraskeletal chondrosarcoma in Fossa poplitea for many years. This rare, highly malignant tumor occurred in unusual location and at unusual age. Histologically, it presented with sheets of primitive mesenchymal cells and islets of well-differentiated cartilaginous tissue. Immunohistochemical preparations revealed a positivity for neuron-specific enolase and vimentin, the cartilaginous portion of the tumor and isolated cells of the undifferentiated area also stained partially for S-100 protein. Three years later, only one metastasis was found in the contralateral lower extremity.
Asunto(s)
Condrosarcoma Mesenquimal/patología , Rodilla , Neoplasias de los Tejidos Blandos/patología , Anciano , Anciano de 80 o más Años , Condrosarcoma Mesenquimal/química , Femenino , Humanos , Inmunohistoquímica , Neoplasias de los Tejidos Blandos/químicaRESUMEN
Seventy-nine cases of small round cell tumors involving bone were studied in an attempt to learn whether the immunohistochemical features of the lesions might allow distinction of small cell osteosarcoma from other potential differential diagnostic considerations, including Ewing's sarcoma, atypical Ewing's sarcoma, primitive neuroectodermal tumor, mesenchymal chondrosarcoma, lymphoma, and the Askin tumor. The tissues studied were all formalin-fixed, decalcified, paraffin sections from patients between the ages of 16 and 48 years. With one exception (a small cell osteosarcoma), none of the lesions was cytokeratin positive. Moreover, none of the lesions was epithelial membrane antigen, desmin, factor VIII-related antigen, synaptophysin, or Leu-M1 positive. Accordingly, strong positivity for these antibodies in a majority of tumor cells should prompt inclusion of tumor types other than those listed above in the differential diagnosis. Vimentin positivity was seen in a majority of the tumors studied irrespective of histologic type. Scattered tumor cells (< 25%) showed positivity with antibodies to muscle-specific actin and smooth muscle actin in several of the different tumor types studied. No lesions other than lymphoma were leukocyte-common antigen (LCA) positive; all but two lymphomas were LCA positive, while all but one lymphoma were L26 positive. One (lymphoblastic) lymphoma was LCA and L26 negative. S-100, neuron-specific enolase, and Leu-7 did not prove to be specific for "neural-associated" tumors, but rather appeared in some small cell osteosarcomas, Ewing's sarcomas, atypical Ewing's sarcomas, primitive neuroectodermal tumors, mesenchymal chondrosarcomas, lymphomas, and Askin tumors. Antibody to cell surface antigen HBA71 was positive in three Ewing's sarcomas (two typical and one atypical) and negative in small cell osteosarcoma (three cases), mesenchymal chondrosarcoma (two cases), and lymphoma (one case). While some guidance may be derived from analysis of immunohistochemical staining patterns in a given lesion, the results reported in the present study do not suggest that routine immunohistochemistry alone will permit distinction of these small cell tumors of bone from one another. The value of immunohistochemical studies appears to lie particularly in the use of antibodies to LCA and S-100 protein to distinguish lymphoma and mesenchymal chondrosarcoma, and perhaps antibody to HBA71 to distinguish neural family lesions (such as Ewing's sarcoma), from other small cell tumors, such as small cell osteosarcoma.